Get the Stockscreener App
4.13
8.97%
0.34
Annovis Bio Inc stock is traded at $4.13, with a volume of 1.04M.
It is up +8.97% in the last 24 hours and up +69.96% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$3.79
Open:
$3.77
24h Volume:
1.04M
Relative Volume:
0.59
Market Cap:
$109.46M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-2.0245
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
-9.23%
1M Performance:
+69.96%
6M Performance:
+40.48%
1Y Performance:
-25.72%
1-Day Range:
$3.70
$4.23
1-Week Range:
$3.70
$4.6399
52-Week Range:
$1.11
$5.60
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
4.13 | 100.45M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com Canada
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com
Published on: 2025-12-08 04:36:17 - moha.gov.vn
Annovis Bio Inc. (ANVS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Annovis Bio Inc. stock a top hedge fund pickEarnings Beat & High Conviction Buy Zone Picks - Newser
Why institutional investors increase stakes in Annovis Bio Inc. stockEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
Why Annovis Bio Inc. stock fits value portfoliosJuly 2025 Summary & Low Risk High Reward Ideas - Newser
Why Annovis Bio Inc. stock is a must watch tickerEarnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Annovis Bio (ANVS) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
How Annovis Bio Inc. stock compares with top peers2025 Price Targets & Weekly Stock Breakout Alerts - Newser
How geopolitical risks impact Annovis Bio Inc. stockWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga
Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting - citybuzz
Annovis Bio, Inc. to Present At the 2025 Annual Meeting of the Parkinson Study Group - marketscreener.com
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - The Manila Times
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise - MSN
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Certain Warrants of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener
Why analysts remain bullish on Annovis Bio Inc. stock2025 Earnings Impact & Daily Profit Focused Stock Screening - moha.gov.vn
Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock - MarketBeat
Annovis Bio : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Annovis Bio director Hoffman buys $159k in shares By Investing.com - Investing.com Nigeria
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
Annovis Bio director Hoffman buys $159k in shares - Investing.com
Annovis Bio Director Michael B Hoffman Buys 39,200 Shares - TradingView
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MyChesCo
Annovis Announces Two Presentations at the CTAD 2025 Conference - The Manila Times
Annovis Bio director Hoffman buys $69.9k in ANVS stock By Investing.com - Investing.com Nigeria
Annovis Bio director Hoffman buys $69.9k in ANVS stock - Investing.com
Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS] - TradingView
Will Annovis Bio Inc. stock attract long term capital inflows2025 Short Interest & Intraday High Probability Setup Alerts - newser.com
How Annovis Bio Inc. stock reacts to stronger dollarJuly 2025 Technicals & Long-Term Safe Investment Ideas - newser.com
Annovis Bio Inc Stock Analysis and ForecastDividend Stability Analysis & Small Budget Capital Growth - earlytimes.in
How Annovis Bio Inc. stock reacts to monetary easingTake Profit & Verified Momentum Watchlists - newser.com
Can Annovis Bio Inc. stock deliver sustainable ROEWeekly Stock Report & Daily Volume Surge Trade Alerts - newser.com
Will Annovis Bio Inc. stock benefit from automationJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):